Leap Therapeutics, Inc. — FY2019 Form 10-K
Entity note: The request identifies Cypherpunk Technologies Inc., but the supplied filing is Leap Therapeutics, Inc. This summary covers Leap’s fiscal year ended December 31, 2019, not a standalone fourth quarter.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. It had no approved products and generated no product-sales revenue. Its lead program was DKN-01, an anti-DKK1 antibody in clinical trials across several cancer types. In November 2019, Leap deprioritized continued development of TRX518 and shifted emphasis toward DKN-01.
Financial performance, liquidity, and obligations
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $24.4 million | $21.8 million |
| General and administrative expense | $9.1 million | $8.9 million |
| Net loss | $32.9 million | $23.1 million |
| Net loss per basic share | $1.47 | $1.64 |
| Cash used in operating activities | $26.9 million | $26.0 million |
| Cash and cash equivalents at year-end | $3.9 million | $16.3 million |
- Operating loss was $33.5 million in 2019 versus $30.8 million in 2018. Margins are not meaningful because Leap had no product-sales revenue.
- At December 31, 2019, current assets were $4.2 million and current liabilities were $8.5 million, a working-capital deficit of about $4.2 million. Total liabilities were $9.2 million; these included $1.0 million of lease liabilities. The balance sheet reported no conventional borrowing debt.
- Management said year-end cash, combined with the subsequent $25.3 million net proceeds from a January 2020 private placement and a $3.0 million BeiGene upfront payment, was expected to fund operations for at least 12 months from issuance of the financial statements.
- Contractual obligations at year-end totaled $1.3 million, including $1.1 million of operating lease commitments and $0.2 million of non-cancellable research/manufacturing commitments.
Material changes versus 2018
- Net loss increased by $9.8 million. Operating expenses rose $2.7 million, while 2018 included a $7.3 million non-cash gain from a decrease in the fair value of warrant liabilities that did not recur in 2019.
- R&D expense rose $2.5 million: DKN-01 spending increased $0.5 million to $16.1 million, and TRX518 spending increased $2.0 million to $8.2 million. Management attributed the increase mainly to higher clinical-trial costs and staffing, partly offset by lower manufacturing and consulting costs.
- Cash declined by $12.4 million during 2019. Financing activities provided $14.8 million, principally from the February public offering and later stock sales.
- Adoption of new warrant accounting guidance moved the 2017 warrants from liability to equity. A $0.4 million down-round feature was recorded as a dividend attributable to common stockholders in 2019.
Outlook, commentary, risks, and unusual items
- Pipeline: DKN-01 clinical results included responses and disease control in several small, early-stage studies. For example, the 300 mg DKN-01/gemcitabine/cisplatin biliary-tract cohort reported a 21.3% partial-response rate and 87.2% disease-control rate. These are preliminary clinical findings, not evidence of regulatory approval or established efficacy.
- BeiGene agreement: In January 2020, BeiGene paid $3.0 million for an option to obtain an exclusive DKN-01 license in Asia (excluding Japan), Australia, and New Zealand. Leap may receive an option-exercise payment, up to $132 million in development, regulatory, and sales milestones, and tiered royalties; future payments are contingent and uncertain.
- Financing and dilution: The January 2020 private placement generated about $25.3 million net. Preferred-stock conversion was approved in March 2020, with related pre-funded warrants and additional warrants also disclosed. The filing also describes anti-dilution provisions in existing warrants; investors should assess the resulting fully diluted share count.
- Principal risks: Continued losses and need for additional capital; clinical-trial, regulatory, enrollment, and commercialization uncertainty; reliance on contract manufacturers and research organizations; dependence on BeiGene’s decisions and performance; competition; and intellectual-property challenges. Two European patent disputes concerning TRX518 remained under appeal.
- Other uncertainties: Management warned that COVID-19 could disrupt trial enrollment, medical-site activity, laboratory testing, and supply chains. Australian R&D incentive income fell to $0.1 million from $0.8 million; continued eligibility and program terms were uncertain.
- The auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Key facts for investors to verify
- Whether DKN-01 results are confirmed in adequately sized, controlled trials and whether biomarker-based patient selection is validated.
- BeiGene’s option-exercise decision, development plans, and the conditions attached to potential milestones and royalties.
- Cash runway against actual operating burn, future trial costs, and any additional financing requirements.
- The fully diluted share count after the preferred-stock conversion, pre-funded warrants, other warrants, and options.
- Progress and outcomes of the European TRX518 patent appeals, and any resulting effect on intellectual-property protection.